Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 15Myeloid 10Lymphoid 6Classical hematology 3Plasma cell 2Other neoplasm 1CNS 1

Conditions

Non-Malignant Neoplasm 1

Interventions

fludarabine 5Educational Status 5fludarabine phosphate 4Whole-Body Irradiation 4Mycophenolic Acid 4Methods 4Melphalan 4Magnetic Resonance Spectroscopy 4Early Intervention, Educational 4Cyclophosphamide 4Busulfan 4Biopsy 4Taxes 3Tacrolimus 3Specimen Handling 3Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Interviews as Topic 3venetoclax 2Sirolimus 2Patient Reported Outcome Measures 2Nivolumab 2Mesna 2Health Promotion 2Colposcopy 2Cisplatin 2Aminolevulinic Acid 2Albumin-Bound Paclitaxel 2toripalimab 1tirbanibulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematopoietic Stem Cell Transplantation × Other neoplasm × 1 year × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡